MDS is mainly diagnosed in elderly patients, with an annual incidence of 4.9/100,000 person/year, increasing up to 20–50 cases after the age of 60. In 2022, two classifications for MDS/AML have been published, an update of the WHO classification and the International Consensus Classification...
or chemotherapy may be all viable options in HR-MDS, although more studies are needed to determine the precise allocation of these therapy. The use of pregraft therapy may prevent transformation into AML in cases whereby the transplantation cannot be performed in a...
Concomitant disorders are indeed common in this aged population; in particular, infection and the presence of anemia were more frequent in elderly patients. Whereas younger age may be a favorable factor for survival with lenalidomide, the more severe disease characteristics seen in patients aged <65...
41 The gain in life expectancy was 4 years when HSCT was performed in MDS patients with intermediate risk according to WPSS, in contrast to patients considered intermediate-1 risk according to IPSS.64 The difference between the 2 risk classifications is mainly based on the consideration of ...
15% of cases occur after Published Online chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people. The March 21, 2014 pathophysiology involves cytog ic changes with or without gene mutations and widespread gene hypermethylation S0140-6736(13)61901-7 at ...
In the last few years, the introduction of RIC regimens has resulted in a significant reduction of transplant-related toxicity and mortality, leading to a rapidly growing number of transplantations in elderly patients with hematologic diseases.30,38 Interestingly, IPSS-R maintained its prognostic effec...
Experience gained in hereditary iron-loading anemias indicates that the long-term consequences of iron toxicity are preventable and reversible by effective iron chelation therapy (ICT). With the introduction of orally effective iron chelators that are easy to take and suitable for use in elderly ...
HRQoL Should Be the Primary Treatment Goal and Needs a Standardized Unit of Measurement Lower-risk myelodysplastic syndromes are known to occur predominantly in the elderly population, who are not eligible for allogeneic transplantation. In this setting the condition is uncurable. The median age at ...
Whether or not this has a positive effect on health-related quality of life should be the main question. 2. HRQoL Should Be the Primary Treatment Goal and Needs a Standardized Unit of Measurement Lower-risk myelodysplastic syndromes are known to occur predominantly in the elderly population, who...
Whether or not this has a positive effect on health-related quality of life should be the main question. 2. HRQoL Should Be the Primary Treatment Goal and Needs a Standardized Unit of Measurement Lower-risk myelodysplastic syndromes are known to occur predominantly in the elderly population, who...